-
2025-521634-29-00
5
2026-03-02
Acute Myeloid Leukemia
-
2024-517899-38-00
4
2026-02-25
Clear Cell Renal Cell Carcinoma (ccRCC)
-
2024-510575-38-00
10
2026-02-24
Relapsed and refractory mature B-cell non-Hodgkin Lymphoma
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-522108-26-00
4
2026-02-19
métastatique colorectal cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-522184-15-00
7
2026-02-18
Advanced Solid Tumor, Metastatic Solid Tumor
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2025-522914-22-00
3
2026-02-11
Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
-
2025-523758-15-00
7
2026-02-11
Cancer
-
2025-522139-33-00
7
2026-02-10
Advanced or metastatic solid tumours
-
2025-523273-41-00
7
2026-01-30
Metastatic castration-resistant prostate cancer
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-521828-30-00
9
2026-01-27
Advanced Solid Tumors
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2023-505781-28-00
4
2026-01-20
Patients with Waldenstrom macroglobulinemia and have received at least
-
2025-521441-24-00
7
2026-01-19
Advanced or Metastatic Solid Tumors
-
2025-522082-29-00
1
2026-01-16
Locally advanced (unresectable) or metastatic solid tumor malignancies
-
2025-522127-95-00
4
2026-01-12
NEOREM: Localized solid malignancies that are eligible to receive neo-